{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:39:54Z","timestamp":1791257994168,"version":"4.1.0"},"reference-count":38,"publisher":"Edizioni Minerva Medica","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Minerva Med"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.23736\/s0026-4806.20.07017-2","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T02:44:48Z","timestamp":1606790688000},"source":"Crossref","is-referenced-by-count":13,"title":["CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia"],"prefix":"10.23736","volume":"111","author":[{"given":"Alessandro","family":"Cafaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria B.","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Silimbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Cangini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Masini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ghelli Luserna Di Ror\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Cerchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17149","reference":[{"key":"10.23736\/S0026-4806.20.07017-2_ref001","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69780-8"},{"key":"10.23736\/S0026-4806.20.07017-2_ref002","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.11.017"},{"key":"10.23736\/S0026-4806.20.07017-2_ref003","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.05.024"},{"key":"10.23736\/S0026-4806.20.07017-2_ref004","first-page":"937","article-title":"The incidence of secondary leukemias","volume":"84","author":"Leone G","year":"1999","journal-title":"Haematologica"},{"key":"10.23736\/S0026-4806.20.07017-2_ref005","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb04253.x"},{"key":"10.23736\/S0026-4806.20.07017-2_ref006","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates JW","year":"1973","journal-title":"Cancer Chemother Rep"},{"key":"10.23736\/S0026-4806.20.07017-2_ref007","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V58.6.1203.1203"},{"key":"10.23736\/S0026-4806.20.07017-2_ref008","first-page":"1441","article-title":"Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study","volume":"69","author":"Preisler H","year":"1987","journal-title":"Blood"},{"key":"10.23736\/S0026-4806.20.07017-2_ref009","first-page":"257","article-title":"Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia","volume":"3","author":"Estey E","year":"1989","journal-title":"Leukemia"},{"key":"10.23736\/S0026-4806.20.07017-2_ref010","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0785"},{"key":"10.23736\/S0026-4806.20.07017-2_ref011","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2990"},{"key":"10.23736\/S0026-4806.20.07017-2_ref012","doi-asserted-by":"crossref","unstructured":"Jazz Pharmaceuticals. VYXEOS\u2122 (daunorubicin and cytarabine) liposome for injection, for intravenous use: US prescribing information; 2017 [Internet]. Available from: http:\/\/www.fda.gov [cited 2020, Oct 1].","DOI":"10.51731\/cjht.2021.183"},{"key":"10.23736\/S0026-4806.20.07017-2_ref013","unstructured":"European Medicines Agency. Vyxeos 44 mg\/100 mg powder for concentrate for solution for infusion: EU summary of product characteristics; 2018 [Internet]. Available from: http:\/\/www.ema.europ a.eu [cited 2020, Oct 1]."},{"key":"10.23736\/S0026-4806.20.07017-2_ref014","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.06.028"},{"key":"10.23736\/S0026-4806.20.07017-2_ref015","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.5961"},{"key":"10.23736\/S0026-4806.20.07017-2_ref016","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2011.04.001"},{"key":"10.23736\/S0026-4806.20.07017-2_ref017","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0118"},{"key":"10.23736\/S0026-4806.20.07017-2_ref018","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.07.006"},{"key":"10.23736\/S0026-4806.20.07017-2_ref019","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.01.015"},{"key":"10.23736\/S0026-4806.20.07017-2_ref020","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-540971"},{"key":"10.23736\/S0026-4806.20.07017-2_ref021","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.027"},{"key":"10.23736\/S0026-4806.20.07017-2_ref022","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28974"},{"key":"10.23736\/S0026-4806.20.07017-2_ref023","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0116"},{"key":"10.23736\/S0026-4806.20.07017-2_ref024","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6112"},{"key":"10.23736\/S0026-4806.20.07017-2_ref025","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"10.23736\/S0026-4806.20.07017-2_ref026","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.7035"},{"key":"10.23736\/S0026-4806.20.07017-2_ref027","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2019.05.005"},{"key":"10.23736\/S0026-4806.20.07017-2_ref028","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3724"},{"key":"10.23736\/S0026-4806.20.07017-2_ref029","doi-asserted-by":"crossref","unstructured":"Lancet J, Feldman E, Cortes J, et al. CPX-351 can induce remission in AML immediately after failed induction with cytarabine and daunorubicin. Proceedings of ASCO 2010 Annual Meeting, 2010 Jun 4-8; Chicago, IL, USA.","DOI":"10.1200\/jco.2010.28.15_suppl.6572"},{"key":"10.23736\/S0026-4806.20.07017-2_ref030","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1513847"},{"key":"10.23736\/S0026-4806.20.07017-2_ref031","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.03.012"},{"key":"10.23736\/S0026-4806.20.07017-2_ref032","unstructured":"National Institute for Health and Care Excellence. Liposomal cytarabine-daunorubicin for untreated acute myeloid leukaemia; 2018 [Interntet]. Available from: http:\/\/www.nice.org.uk [cited 2020, Oct 1]."},{"key":"10.23736\/S0026-4806.20.07017-2_ref033","first-page":"130","article-title":"Cost-effectiveness of CPX-351 versus 7 + 3 regimen in the treatment of treatmentrelated acute myeloid leukemia (tAML) or AML with myelodysplasia-related changes (MRC). Abstract no. 4674","volume":"\u2022\u2022\u2022","author":"Kansal A","year":"2017","journal-title":"Blood"},{"key":"10.23736\/S0026-4806.20.07017-2_ref034","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4354"},{"key":"10.23736\/S0026-4806.20.07017-2_ref035","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02527.x"},{"key":"10.23736\/S0026-4806.20.07017-2_ref036","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11034"},{"key":"10.23736\/S0026-4806.20.07017-2_ref037","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-301713"},{"key":"10.23736\/S0026-4806.20.07017-2_ref038","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24367"}],"container-title":["Minerva Medica"],"original-title":[],"link":[{"URL":"https:\/\/www.minervamedica.it\/pdf.php?cod=R10Y2020N05A0455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T11:35:35Z","timestamp":1669894535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.minervamedica.it\/index2.php?show=R10Y2020N05A0455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":38,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.23736\/s0026-4806.20.07017-2","relation":{},"ISSN":["0026-4806","1827-1669"],"issn-type":[{"value":"0026-4806","type":"print"},{"value":"1827-1669","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}